Frontier Medicines Archives – Droia Ventures

19 Jul Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline

Posted at 12:00h in Frontier Medicines

Funding to Enhance Research and Development of Pipeline, Including Lead Program Targeting Activated KRAS^G12C. Proceeds to Further Accelerate the Development of Foundational Technologies in Chemoproteomics, Covalent Drug Discovery and Machine Learning. Distinguished Scientific Advisory Board Announced. Expansion of Frontier Operations with Opening of Boston Facility...

02 Dec Frontier Medicines and AbbVie establish global partnership to discover and develop novel therapies and E3 degraders against difficult-to-drug targets

Posted at 22:08h in Frontier Medicines

Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases. Frontier eligible to receive up to $100 million in upfront and milestone payments within the first 12 months of collaboration....

11 Nov Chemical & Engineering News Names Frontier Medicines One of Its 10 Chemistry Start-Ups to Watch

Posted at 16:15h in Frontier Medicines

C&EN writers and editors scoured the start-up landscape for standouts and reader nominations. These fledging firms are being recognized for their world-changing chemistry innovations and bringing them to market....

23 Sep FierceBiotech Names Frontier Medicines One of Its “Fierce 15” Biotech Companies of 2019

Posted at 06:55h in Frontier Medicines

“This year has seen unrivalled scientific talent in the early-stage life sciences world. It has been a pleasure to for us at FierceBiotech to speak to all 15 winners and hear their passion, progress and panache,” said Ben Adams, Senior Editor of FierceBiotech. “Each company...

31 Jul Frontier Medicines Announces Three Executive Hires: Chief Scientific Officer, Chief Technology Officer & Head of Degrader Technologies

Posted at 09:21h in Frontier Medicines

“We are thrilled to welcome Kevin, Johannes and Jim to Frontier Medicines as we continue to build a best-in-the-business team to address previously inaccessible disease-causing proteins,” said Chris Varma, Ph.D., co-founder and CEO of Frontier Medicines. “Kevin, Johannes and Jim bring deep science, biopharma and...

25 Jun Frontier Medicines Launches with $67 Million to Develop Novel Medicines that Drug the “Undruggable” Targets Driving Human Disease

Posted at 09:28h in Frontier Medicines

“Our platform currently includes a database of hotspots that cover a majority of human proteins, including those that were previously considered ‘undruggable;’ an expanding library of diverse, covalent compounds being driven by machine learning; and a novel approach to protein degradation,” said Daniel K. Nomura,...